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We are investigating whether skin-targeted gene 
therapy may be used to treat hemophilia B by trans-
planting keratinocytes transduced by factor IX-ex-
pressing retroviral vectors. No pre-clinical animal 
model for keratinocyte-mediated gene therapy has 
shown long-term efficacy in vivo. It remains unclear 
whether this short-term expression is due to pro-
moter shut-off or a reduced survival of grafted genet-
ically modified cells. The purpose of this study was to 
determine the fate of primary human keratinocytes 
superficially grafted to nude mice in a silicone trans-
plantation chamber. In addition, vectors containing 
keratinocyte-specific enhancers from the human 
papilloma virus-16 (HPV-16) and human keratin 5 
and 14 genes were used upstream of the cytomegalo-
viral (CMV) immediate-early promoter/enhancer to 
T he keratinocyte, the major cell type of the epidermis, is an attractive target cell for the purpose of ex vivo gene therapy (reviewed by Greenhalgh et al, 1994). The epidermis can be noninvasively biopsied to provide a source of keratinocytes (Rheinwald, 1989) 
that can be serially cultivated (Rheinwald and Green, 1975), 
transduced by retroviruses, and expanded to large numbers in 
culture (Green et al, 1979). In addition, procedures for autografting 
keratinocytes onto btun victims are well established (Gallico et al, 
1984). Furthermore, these grafts remain visible, enabling easy 
monitoring (e .g., for signs of malignancy) and removal if necessary. 
As a result, the epidermis has become the focus of many gene 
therapy protocols, using not only an ex IJillo retroviral approach 
(Morgan et al, 1987; Gerrard et al, 1993; Stockschlader et al, 1994; 
Choate et al, 1996) but also a direct i11 11i110 approach with adenoviral 
vectors (Setoguchi . et al, 1994; Bonnekoh et a/, 1995), topically 
applied DNA-liposome complexes (Alexander and Akhurst, 1995; 
Li and Hoffinan, 1995), or direct injection of naked DNA (Katsurni 
et al, 1994; Hengge et al, 1995). 
Genetically modified epidermis can theoretically be used to treat 
a diverse range of diseases, either as a bioreactor to systemically 
deliver proteins such as clotting f.'lctors (Gerrard et al, 1993; 
Brownlee, 1995; Fenjves et al, 1996), growth hormone (Morgan et 
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control factor IX eDNA expression to avoid promoter 
shut-off. Factor IX was secreted by cultured kerati-
nocytes after transduction by each of these chimeric 
promoter/enhancer vectors, although the levels var-
ied according to the particular construct used. Kera-
tinocytes transduced by the vector containing the 
HPV-16 enhancer were grafted into nude mice, and 
human factor IX was detected in plasma at 0.02-9 ng 
per ml for 4-5 wk for the duration of graft survival. 
The HPV-16 enhancer may be a useful addition to 
expression vectors for keratinocyte gene therapy. 
The transplantation chamber can be adapted to graft-
ing retrovirally transduced keratinocytes for gene 
transfer studies. Key JVords: retroviral vector/epidermis/ 
factor IX/skiu grafting. J ltwest Dermatol 109:139-145, 
1997 
al, 1987; Jensen et al, 1994), and a 1-anti-trypsi.J1 (Setoguchi et al, 
1994) or as a metabolic sink to remove toxic products from the 
circulation, e.g., by expression of adenosi.J1e deaminase (Stock-
sch.lader et al, 1991). Altematively, gene therapy may be applied to 
treat i.J1herited (Choate et a/, 1996) or acquired (Botmekoh et al, 
1995) disorders of the skin and might be useful in accelerating 
healing of epithelial autografted bum victims (Gallico et al, 1984). 
Previously we have shown that normal human keratinocytes, 
transduced by a retroviral vector in which the human clotting factor 
IX eDNA was nnder the transcriptional control of the Moloney 
murine leukemia 5 ' long terminal repeat (LTR) promoter/ en-
hancer, were able to secrete - 600 ng of fuctor IX per 106 cells per 
24 h in tissue culture. When these cells were grafted beneath a skin 
flap in athymic mice, however, the levels of human factor IX 
detected in the plasma ( - 3 ng per ml) were lower than e:A"Pected. 
Moreover, factor IX rapidly decli.J1ed and was not detected after 1 
wk. The low levels and short duration of e:A'Pression in vivo may 
have been a result of (i) a change i.Jt transcriptional activity of the 
promoter after transplantation; (ii) the "ectopic" environment of 
the graft affecting the growth, differentiation, and life-span of the 
transplanted keratinocytes; or (iii) i.Jtadequate transport of factor IX 
to the circulation via lymphatic drainage. This latter possibility is 
unlikely, however, because reasonably efficient transport of factor 
IX from a subcutaneous site to the bloodstream was demonstrated 
in model e:A"]Jeriments (Gerrard et al, 1992), and factor IX expres-
sion directed to the naturally formed (i. e ., nongrafted) epidermis in 
a transgenic mouse resulted in its transport to the blood (Alexander 
et al, 1995). 
Similar in vi11o observations of low and decreasing recombinant 
gene product under d1e transcriptional control of strong viral 
promoters (such as the cytomegalovirus (CMV) or retroviral LTR] 
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CLONES FUNCTIONAL BEST BEST VIRAL 
SECRETING CLONEsb CLONEC TITERd 
VIR USa (cfu/106cells/24 hrs) VECTOR 
LNCIX ell 4x103 
LNPCIX Factor IX eDNA LTR 17/26 8/26 c23 6x103 
LNK14CIX Factor IX eDNA LTR 4/27 1127 c13 <5x102 
Factor IX eDNA LTR 11/28 1/28 c12 2xl06 
LNK5CIX Factor IX eDNA LTR 15/28 5/28 c22 8x105 
. t-1 ----il . D II II 
·•· Scale=l kb HPV-16 hK14 hK14 (reverse) hK5 
Figure 1. Rctroviral vectors containing kcratinocytc-spccific enhancer clements. Vector nomenclature is derived from the individual ·components 
of the construct: L, LT R; N , ueo (neomycin phosphotransferase selectable marker); C, CMV (immediate-early CMV promoter/enhancer); IX, human 
dotting factor IX eDNA; P, keratinocyte dependent enhancer from HPV-16; K5/K14, transcriptional sequence from the 5' noncoding region ofh.K5 and 
h.K14 genes, respectively; K14R, reverse orientation. PA317 producer cell clones were isolated for each of these vectors with the exception of 
PA3l7-LNCIXcll, which had been previously isolated (Palmer eta/, 1989). Footnotes to figure are as follows: "The number ofPA317-producer clones 
secreting vi.rus over the total number isolated for each construct; bThe number ofPA317-producer clones secreting virus and human factor IX over the total 
number isola ted; cBest clone refers to the clone reference number with the highest viral titer; dThe viral titer of the best clone. 
have been reported by others in keratinocytes (Fenjves et al, 1996), 
fibroblasts (Pabner et al, 1989), myoblasts (Dai et al, 1992), 
hepatocytes (Kay et al, 1992), and hematopoietic stem cells (Chal-
lita and Kohn, 1994) . In some cases, persistence of vector DNA but 
declining levels of mRNA suggested that the decrease in recombi-
nant protein may be a result of promoter down-regulation (Palmer 
et al, 1991; Scharfina.~m et al, 1991; Challita and Kohn, 1994; 
Dwarki et al, 1995). This problem of viral promoter shut- off has 
been partly overcome by the use of non viral promoters such as the 
phosphoglycerate kinase (Moullier et al, 1993), the dihydrofolate 
reduc tase (Scharfmann et al, 1991), the metalloth.ionein (Heartlein 
et al, 1994), the /3-actin (Chowdhury et al , 1991), the polymerase II 
(Rettinger et al, 1994), or the human a 1-anti-trypsin (Hafenrichter 
et at, 1994) prornoter. Despite the obvious success in achieving 
long-term expression in vitJO, however, these "housekeeping" or 
tissue- specific promoters are generally much less active than viral 
promoters (Yao et al, 1991; Cheng et al, 1993; Rettinger et al, 
1994) . By using hybrid promoter/enhancer elements to combine 
the dual benefits of a strong promoter with the long-term effects of 
tissue-specific enhancers, Dai et al (1992) and Okuyama et al (1996) 
achieved sustained detectable levels of trans gene expression in 11ivo. 
Not all combinations of promoter/enhancer hybrids, however, 
were successful (Dai et al, 1992; Wu et al, 1996). 
Herein we sought to improve the duration and level of factor IX 
expression in vivo in a nude mouse modeL We have investigated a 
superficial skin grafting technique as an alternative to grafting 
kerat:inocytes in an "ectopic" position beneath a skin flap, as we 
have previously reported (Gerrard et al, 1993). Keratinocytes were 
transplanted onto a superficial position of the skin of an a thymic 
mouse within a silicone transplantation chamber. This chamber 
(Boukamp et al, 1985), used herein as part of a gene therapy 
protocol, protects the grafted keratinocytes from desiccation and 
mechanical irritation while enabling tissue architecture to form. 
Furthermore, the chamber defines the lim.its of the wound margin 
by preventing graft shrinkage and host-mediated re-epithelializa-
tion of the graft bed thus enabling the contribution of surviving 
bona fide transplanted cells to the re-formed epithelium to be 
determined without ambiguity. Retroviral vectors were con-
structed in which factor IX expression was controlled by the strong 
CMV immediate-early promoter/ enhancer and keratinocyte-spe-
cific enhancer elements from either human papilloma virus 16 
(HPV- 16; Cripe et al, 1987) or just upstream of the human keratin 
14 (hK14) Giang et al, 1990; Leask et a/, 1990) or the human keratin 
5 (hK5) (Ohtsuki et al, 1992; Byrne and Fuchs, 1993) genes. Factor 
IX produced from keratinocytes transduced by each of these 
vectors was assessed in vitro (tissue culture) and in. 11i1Jo after 
superficial transplantation to nude mice. 
MATERIALS AND METHODS 
Construction ofRetroviral Vectors The human factor IX eDNA was 
excised from pKG5IX-2- a modified version of pKG5IX-l (Rees et a/, 
1988), correcting a short nucleotide rearranged section present in earlier 
constructs (Anson eta/, 1985; Gerrard eta/ , 1993)-with Hi~tdlll and Xlwl , 
subcloned into pBiuescript KS + (Stratagene) to generate pBS- FIX, re-
excised with Ba111HI, "fllled-in" with the Klenow fragment of DNA 
polymerase I, and finally cloned into Hpal-cut pLNCX (Miller and Ros-
man, 1989) to generate pLNCIX. All other vectors were derived from tllis 
vector by amplifying keratinocyte enhancer elements by Pji.1 (Stratagene) 
polymerase chain reaction and cloning the Ba1111-II-digested products into 
Ba111Hl-digested pLNCIX (Fig 1): pLNPCIX contained the enhancer 
region from positions 7500 to 7777 of the 1-IPV-16 genome (Seedorf et a/, 
1985) and was constructed by using the primers 5'-ACCGGGATCCTTC-
TATGTCAGCAACTATGG-3' (forward) and 5'-ACCGGGATCCCATT-
TAGTTGGCCTTAGAAG-3' (reverse); pLNK14CIX and pLNK14RCIX 
contained the proximal domain (positions -271 to - 30) from upstream of 
the h.K14 gene (Leask et nl, 1990) in the forward and reverse orientation, 
respectively , and was constructed by using tl1e primers 5' -ACCGGGATC-
CTGAGGGCTGGGACTCCCAG-3' (forward) and 5'-ACCGGGATC-
CTCATGGGTAGGGGGCGGGTC-3' (reverse); pLNK5CIX contained 
the region from positions - 102 to - 29 npstream of the hK5 gene (Byrne 
and Fuchs, 1993) amplified with the primers 5'-CGGGGTACCGGATC-
CGCCCCCCAGGCATGCCCAGCCCACTT AA TC-3' (forward) and 5 '-
CGCCGCTCGAGGATCCCTTCCAGAACTGGGCT-3' (reverse). Poly-
merase chain reaction fidelity and the orientation of cloned inserts was 
verified by automated DNA sequencing. 
Cell Culture: Generation of Defective Retroviral Vector Producer 
Cell Lines and Transduction of Human Kcratinocytcs Defective 
retroviral vector producer cell lines were generated as previously described 
(Miller eta/, 1993). Briefly, tl1e packaging cell line 1/J-2 (Mann eta/, 1983) 
was transiently transfected with vector plasmid and the resulting defective 
virus was used to transduce the packaging cell line PA317 (Miller and 
Buttimore, 1986). Individual colmlies of G418-resistant PA317 vector 
producer cells were isolated and the viral titer was determined on 3T3 tk-
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cells, essentially as described (Miller et a!, 1993). The \]ICIUP-MFG-NB 
producer cell line secretes the retroviral vector MFG- NB, which contains 
the nuclear-localized /3-galactosidase marker under the control of the 
retroviral LTR promoter/enhancer and lacks a 11co selectable marker (Ferry 
et a/, 1991 ). Low-passage (less than ftve passages) normal human foreskin 
keratinocyte stra ins kk, ka, a, or z were transduced by co- cultivation with 
lethally irradiated PA317 vector producer cells (Gerrard et a/, 1993). 
Transduced keratinocytes were selected in 0.15 mg G418 per ml for 2 wk 
with the exception of cells transduced by 'VCRIP-MFG-NB, which were 
grafted without selection. 
Quantitation of Human Factor IX by Enzyme-Linked lmmunosor-
bent Assay (ELISA) Human factor IX in conditioned medium from 
transduced keratinocytes and PA317 producer cells was measured by ELISA 
(limit of sensitivity - 0.1 ng per ml) as previously described (Anson et a/, 
1985) using the monoclonal anti-human factor IX antibody 3A6 (Yoshioka 
et al, 1985) and polyclonal rabbit anti-human factor IX (Dako, High 
Wycombe, UK) followed by peroxidase-conjugated goat anti-rabbit IgG 
(Stgma, Poole, UK) as the primary and secondary detection antibodies, 
respectively. For quantitating human factor IX in mouse plasma, samples 
were diluted in phosphate-buffered saline containing 0.1 %, Triton X-100, 20 
mg bovine serum albumin per ml, and 1 mM ethylenediamine tetraacetic 
acid, and the sensitivity of the ELISA was improved over that described by 
At.lSOn et a/ (1985) to - 0.02 ng per ml by replacing the secondary antibody 
Wlth biotinylated goat anti- rabbit IgG (Vector, Peterborough, UK) fol-
lowed by horseradish peroxidase-avidin conjugate (Vector) before devel-
opment (Anson eta/, 1985). 
Superficial Transplantation of Keratinocytes to Mouse Kerati.no-
cytes were grafted beneath a. silicone transplantation chamber in a one-step 
procedure essentia lly as described (Boukamp et a/, 1985). Briefly, cl1e 
chamber (Renner, Dannestadt, Germany) was embedded beneath the 
full-thickness skin of8- to,tO-wk-old male MF1 Nu/Nu mice (Harlan O lac, 
Btcester, U.K.) and - 10 keratinocytes in 200 pJ of phosphate-buffered 
~a~ne were carefully layered onto the surface of the mouse f.~scia by 
111Jection through the chamber. Blood was collected from the tail vein into 
one-tenth the volume of7.6% sodium citrate, and the plasma was separated 
by microcentrifugation. Animal husbandry and all procedures were per-
formed according to British Home Office regulations. Mice were humanely 
sacnficed and the tissue beneath the chamber was processed for either 
routine hematoxylin and eosin or histochemical (Jensen eta/, 1994) staining. 
RESULTS 
Generation of Defective Retroviral Producer Clones A 
se~ies of retroviral vectors based upon the Moloney murine leuke-
mia virus (Miller and Rosman, 1989) was constructed in which 
the factor IX eDNA was p laced under the transcriptional control 
of either the CMV immediate-early promoter/enhancer alone 
(LNCIX) or a combination of the CMV promoter/enhancer and 
various keratinocyte-speciftc enhancer elements (Fig 1). The vec-
tor LNPCIX contained the 277-bp (positions 7500 - 7777) kerati-
nocyte-dependent viral- independent enhancer upstream of the P97 
promoter of HPV-16 (Cripe et a/ , 1987); LNK14CIX and 
LNK14RCIX contained a 241-bp fragment of the proximal en-
hancer from the hK14 gene Qiang et nl, 1990; Leask et nl, 1990, 
1991) in the forward or reverse m;entation, respectively, and 
LNKSCIX contained 73 bp of sequence immediately 5' of the 
TATA box fi·om the hKS gene (Ohtsuki et nl, 1992; Byrne and 
~uch.s, 1993) (Fig 1). The CMV promoter was selected because "it 
IS one of the strongest known viral promoters in. human cells, 
~1cluding kerati.nocytes (Cheng et al, 1993), and because its activity 
ts up-regulated by a h eterologous enh ancer (e.g., the muscle 
creatine kinase enhancer; Dai et nl, 1992) . The keratinocyte-specific 
enhancers were selected because they are among the best studied 
enhancers known to be active in norma l keratinocytes. 
Defective- retroviral producer clones were generated by standard 
techniques, and the individual clones of G418- resistant PA317 
producer cells were screened for factor IX expression and virus in 
the conditioned medium. Clones were considered "functional" if 
~hey secreted factor IX and had a detectable viral titer (Fig 1). The 
Ulciusion of different keratinocyte-specific enhancer e lements as 
pa:~ of the same parent vector backbone had variable effects on the 
ability to isolate functional virus- secreting producer clones (Fig 1). 
When the LNPCIX construct was used, more than half of the 
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Figure 2. Variations in the levels of factor IX secreted by trans-
duced keratinocytes results from the different retroviral vectors 
used. Conditioned medium from G418-resistant transduced keratinocytes 
was assayed by ELISA and normalized for 106 cells. En·or bars, SEM (n = 
nwnber of independent transductions) . 
clones isolated produced virus and a third also secreted factor IX, 
but when the LNK14CIX construct was used, only 4 of 27 
produced virus and only one clone also secreted factor IX. High-
titer producer clones (- 106 colony-forming units per 106 cells per 
24 h) were isolated for the vectors LNK14RCIX and LNKSCIX. 
Even the best PA317 producer clone isolated for vectors LNPCIX 
and LNK14CIX, however, gave low viral titers (< 104 colony-
fanning units per 106 cells per 24 h) . 
Transduced Keratinocytes Secrete Factor IX into Condi-
tioned Medium Normal human foreskin keratinocytes were 
transduced by each of the five factor IX retroviral vectors (Fig 1) 
by co- cultivation with the corresponding letha.lly irradiated PA317 
producer clone, and the conditioned medium fi.·om G4l8-se!ected 
keratinocytes was assayed for factor IX by ELISA (Fig 2). Trans-
duction was reasonably efficient with the high-titer producer clones 
PA317-LNKSCIXc22 and -LNK14RCIXc12 but was inefficient 
wi.th the lower-titer clones PA317-LNCIXc11 -LNPCIXc23 and 
-LNK14CIXc13 (data not shown). Kerati.nocyt~s transduced b~ the 
parent vector PA317-LNCIXc11 secreted 255 :±: 51 (mean:±: SEM) 
ng of factor IX per 106 cells per 24 h in culture and by PA317-
LNPCIXc23 secreted marginally higher levels of 387 :±: 66 ng of 
factor IX per 106 cells per 24 h (Fig 2), although tins difference is 
not statistically significant in a Student's t test (p > 0 .1). These 
values are also similar to the levels reported for keratinocytes in 
which the factor IX was under the control of the Moloney murine 
leukemia retrovirus LTR promoter/enhancer (Gerrard eta/, 1993; 
Fenjves et nl, 1996). By contrast, keratinocytes t:J:ansduced by 
PA317-LNKSCIXc22 and -LNK14CIXc13 secreted - 10-fold 
lower levels of factor IX at 19 .5 :±: 2.3 and 52 .5 :±: 15.5 ngper 106 
cells per 24 h, respectively, and transduction with PA317-
LNK14RCIXc12 resulted in even lower factor IX levels of 1.6 :±: 
0.13 ng of factor IX per 106 cells per 24 h . 
Human Factor IX Is Detected in Plasm.a of Mice Grafted 
with Transduced Keratinocytes Because the HPV-16 en-
hancer did not inhibit the level of factor IX secreted b y keratino-
cytes ill JJitro (Fig 2), keratinocytes transduced by tins vector were 
142 PAGE AND BROWNLEE 
0.1 
0.02D------r----r------r~>---~---'l:r-1 
0 10 20 30 40 50 
Days post grafting 
Figure 3. Human factor IX is secreted in plasma of nude mice 
grafted with retrovirally transduced keratinocytes. Mice were bled at 
different times after grafting, and human factor IX was assayed by ELISA. 
Mouse 1 (0), mouse 2 (0 ) , mouse 3 ( <> ), and mouse 4 (6 ) were grafted 
with - 1.5 X 107 PA317-LNPCIXc23-transduced keratinocytes. Data 
points derive from single factor IX ELISA assays (because of limited 
volumes of plasma from tail vein bleeds). 
grafted onto nude mice. A silicone transplantation chamber was 
embedded beneath the full-thickness mouse skin and the vector-
transduced keratinocytes were injected as a cell suspension directly 
onto the muscle L'lscia surface within the capsule (Boukamp et al, 
1985). Unlike our previous study (Gerrard et al, 1993) in which 
keratinocytes were "ectopically" transplanted into a subcutaneous 
pocket, by using the tc::chnique reported herein, keratinocytes were 
exposed to the air in the superficial (or epidermal) environment. 
After transplantation, plasma samples were periodically taken from 
mice and assayed for human factor IX by ELISA. Ten mice were 
transplanted with keratinocytes transduced by the producer line 
PA317-LNPCIX.c23, and the results of four mice (mice 1- 4) 
transplanted with - 1.5 X 107 cells are shown in Figure 3. Plasma 
samples taken at 1-5 dafter grafting contained 3-9 ng human factor 
IX per ml. These levels dropped to 0.05-0.35 ng per ml after 
10-20 d and were undetectable(< - 0.02 ng per ml) after 40 d. The 
Figure 4. Histologic analysis shows the 
absence of a normal epidermis correlat-
ing with the loss of factor IX expression 
in plasma. (A) Mouse 11, 7 dafter grafting 
PA317-LNCIXc11-transduced keratinocytes, 
showing stratum corneum on the surface of the 
neodennis. (B) Mouse 3, 34 d after grafting 
PA317 -LNPCIXc23-transduced kerat:inocytes, 
showing no trace of eid1er kerat:inocytes or 
stratum comeum. Scale bars, 200 J.Lm. 
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remaining 6 mice grafted with between 0.2 an 1.5 X 107 keratino-
cytes produced a similar pattern of an initial peak followed by a 
slow decline (data not shown). 
To assay for keratinocyte survival, we sacrificed mice and 
examined the area of tissue beneath the capsu le by histology (Fig 
4). Mouse 11, which had been grafted w ith PA317-LNCIXc11-
transduced keratinocytes, was sacrificed at day 7 after the initial 
levels of - 6 ng factor IX per ml of plastna (day 2) had fallen to 
- 0.25 ng per ml (day 7). All that remained of the grafted 
keratinocytes was an anucleate stratum corneum, with no evidence 
of a basal keratinocyte layer (Fig 4A). The 10 mice grafted with 
PA317-LNPCIXc23 transduced cells were sacriftced after the 
plasma levels of human L'lctor IX had fallen below baseline (Fig 3). 
No trace of either keratinocytes or stratum corneum could be 
detected in the tissue retrieved from any of these mice (e.g., mouse 
3 sacrificed at 34 d is shown in Fig 4B). The apparent discrepancy 
in the observation of mouse 11 at day 7 that keratinocytes were not 
detected histologically (Fig 4A) yet human factor IX was detected 
in plasma may be explained by either the delay in transport of factor 
IX to plasma or by the presence of residual undetected keratino-
cytes in the graft. 
To investigate the fate of transplanted keratinocytes, a set of 
nude mice was grafted with /acZ-marked keratinocytes and grafts 
were retrieved at regular intervals for histochemical analysis. 
Unlike the factor IX- expressing vectors (Fig 1), the MFG-NB 
vector does not carry a neo selectable marker (Ferry et al, 1991); 
keratinocytes were transduced by co- cultivation as before but were 
then directly grafted without G418 selection. Two days after 
transplantation (Fig SA), human kerati:nocytes, as identified by the 
occasional blue histochemical staining, were found along the 
surface of the mouse fascia graft bed. By 6 d (Fig SB), the 
keratinocytes had differentiated to form a mature epidermis com-
plete with the four layers of stratified tissue characteristic of normal 
skin architecture. /3-Galactosidase-positive cells were detected in all 
layers (Fig SC), and the mouse mesenchyme tissue had contracted 
to form a thjck neodermis containing densely packed fibroblasts 
arranged parallel to the surface. After 2 wk, the keratinocytes on 
the surface began to be engulfed by the dense mouse mesenchyme 
tissue (Fig SD) until they became fi.tlly encapsulated to form 
subcutaneous keratinocyte-containing cysts (data not shown). By 4 
wk, the dennis consisted of a very thickened layer of densely 
packed fibroblasts: keratinocytes, however, were not detected, 
either on the surface or buried in the mesenchyme (data not 
shown). 
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Figure 5. LtcZ- marked keratinocytes initially form a viable epidermis that becomes encapsulated over time. (A) After 2 d , human 
keratinocytes (K), as identified by the occasional blue cell, were located along the surf.1ce of the mo use f.1sc ia (F) . (B) High-power micrograph. (C) 
Low-power micrograph. By 6 d , the grafted keratinocytcs had stratified and differentiated to form a characteristic epidennal architectme consisting of basal 
(B), suprabasal (SB), stra tum granu losum (St. G), and stratui11 corneum (St. C) layers . The mouse mesenchyme tissue had contracted to form a thickened 
neodermis (ND) of fibrob lasts . J3-Galactosidase-positive cells were found in all layers of the epidermis (E). (D) After 2 wk, the grafted keratinocytes becam e 
engu.lfed by the mouse mesenchyme to form cys ts of keratinocytes. Scale bars, 100 f.ll11. 
DISCUSSION 
Long-term expression in the differentiated epidermis formed after 
grafting genetically modified keratinocytes is a prerequisite of an ex 
11i11o approach to gene therapy. We therefore used various kerati-
nocyte- specific enhancer elements-not previously studied as part 
of a gene therapy protocol- upstream of a strong CMV promoter/ 
enhancer to control expression of factor IX in retrovirally trans-
duced keratinocytes . 
Defective retroviral producer clones were isolated for each of the 
vector constructs . With some constructs (e.g., LNK14CIX and 
LNK14RCIX), . the addition of the enhancer element affected the 
ability to isolate functional clones, whereas with others (e.g., 
LNPCIX, containing the HPV-16 enhancer) the viral titer of the 
resulting producer clones was reduced. The inclusion of nonretro-
viral elements, especially sequences that are not usually transcribed 
(e.g., upstream regulatory sequences), may affect a number of 
different processes in the life cycle of the virus including transcrip-
tion initiation and elongation, polyadenylation, splicing, transport 
from the nucleus, and reverse transcription. Altematively, heterol-
ogous sequence may alter the secondary structure of transcripts, 
which could affect mR.NA stability and/ or packaging. Any of these 
processes could reduce the levels of full-length vector mRNA 
available for packaging by the W2/ PA317 cell, thereby affecting the 
proportion of functional clones isolated and the viral titer of those 
clones. 
After transduction by the different retroviral vectors, conditioned 
medium from G418-resistant keratinocytes was assayed for factor 
IX antigen as an approximate measure of factor IX eDNA tran-
scriptional act1v1ty. We believe that expression from the 5 ' LTR 
promoter is unlikely to conu;bute significantly to the levels of 
fuctor IX antigen, because translation of the downstream factor IX 
eDNA from the longer LTR-derived a·ansct;pt will be at best 
highly inefficient (Kozak, 1991) . In addition, any residual cona;-
bution to factor IX antigen would be equal for all vectors tested. 
Furthermore, all factor IX transcripts initiated from the internal 
promoter contain identical backbone sequences and should there-
fore be subject to the same mechanisms controlling mRNA stabil-
ity, translational efficiency, and any aberrant spli.cing that might 
affect the level of factor IX antigen. Because transduction was 
inefficient, especially in the case of cells transduced by PA317-
LNCIXc11, -LNPCIXc23, and - LNK14CIXc13 , G418-resistant 
cells are unlikely to contain more than one proviral integration per 
cell. In the case of the LNPCIX vector, the levels of factor IX 
secreted in 11itro were as high as tl1e levels obtained using the parent 
LNCIX vector, indicating that the hybrid HPV-1 6-CMV promot-
er/enhancer must have been as active in keratinocytes as the CMV 
promoter/enhancer alon e. The remaining constructs (containing 
the h.KS and hK1 4 enhancers) produced lower levels of factor IX 
eJ..-pression in 11itro, suggesting that tl1ese enhancer elements inter-
fered with CMV promoter activity . These observations are consis-
tent with the variation in activity witl1 either different promoters 
(Cheng eta/, 1993; Hafenrichter et a/, 1994) or different promoter/ 
enhancer hybrids (Dai et al, 1992; Couture et al, 1994; Okuyama et 
a/, 1996; Wu et a/, 1996) . 
The results with /acZ-marked keratinocytes suggested that trans-
duced keratine>cytes can form a nom1al epidermis and rem ain 
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viable, at least initially, in vivo. The encapsulation process we 
observed contrasts with the results of Boukamp et al (1990) who 
observed encapsulation only with trunk-skin-derived and not with 
foreskin-derived cells, although the reasons for this discrepancy are 
unclear. Encapsulation may be circumvented by transplanting the 
factor IX-secreting keratinocytes on a collagen matrix (Boukamp et 
al, 1990) 
When nude mice were grafted with keratinocytes transduced by 
the LNPCIX vector (containing the HPV-16 enhancer), recombi-
nant factor IX was detected in plasma at levels of between 0.02 and 
9 ng per ml for 4-5 wk, demonstrating that this particular 
combination of promoter/ enhancer is capable of producing detect-
able levels of factor IX itl vi11o. This expression is longer than the 7 d 
of Gerrard et al (1993) and equivalent to the 23-44 d ofFenjves et 
a/ (1996). The longer duration that we observed carmot be 
explained sin1ply by the increased sensitivity (from 0.1 to 0.02 ng 
per ml) of the ELISA over previous studies (Gerrard et al, 1993), 
because factor IX levels of > 0.1 ng per ml were still detected 
beyond 30 d (Fig 3). The levels that we observed are marginally 
higher than the maxinmm levels of 2-3 ng per ml of previous 
studies (Gerrard et al, 1993; Fenjves et al, 1996). 
The question whether the presence of the chin1eric HPV-16 
enhancer contributed to the higher levels and longer duration of 
factor IX expression in vivo remains open. This was not systemat-
ically investigated, although in the single control at1in1al (mouse 11, 
see Results) grafted with cells transduced by the parent (CMV 
promoter/enhancer alone) vector, factor IX expression was of 
short duration (7 d). Tllis may not be a representative experiment, 
however, because of the wide variation in the in vi11o results 
observed for mice 1-10 (see Results and Fig 3). 
Consistent with earlier evidence (Gerrard et al, 1993) showing a 
correlation between the presence of a stratified human epidermal 
graft and human factor IX in plasma, we found that grafts retrieved 
after factor LX levels had fallen to baseline showed no evidence of 
a stratified epidernlis (Fig 4B), although we believe that it is certain 
that an epidemlis did form initially. Because the decli11ing levels of 
recombinant factor IX correlated with the timing of the encapsu-
lation process observed for lacZ-marked keratinocytes, it is likely 
that the factor IX-secreting keratinocytes suffered a similar fate, and 
this is probably the major factor contributing to the loss of factor IX 
expression. Because mouse 11, sacrificed after 7 d, showed only the 
remnants of a stratum corneum along the surface of the graft (Fig 
4A), however, it is possible that terminal differentiation of the 
grafted keratinocytes was an additional factor leading to the loss of 
expression. Because of a poor transduction efficiency with PA317-
LNCIXc11 and -LNPCIXc23, G418 selection may have reduced 
the number of clonogenic stem cells below the threshold required 
for maintaining a grafted epithelium. Furthem10re, G418 is known 
to be cytotoxic to keratinocytes (Stockschlader el al, 1991), thus, 
inducing or accelerating differentiation. Transduced keratinocytes 
were therefore grafted after the minimum time in culture to 
maximize the opportunity of transplanting a stem cell population 
and to obtain at least short-term in 11iT1o data. 
To ensure the long-term maintenance of genetically modified 
keratinocytes in the grafted epithelium, the efficiency of stem cell 
transduction must be improved, possibly by increasing the viral titer 
of defective vectors, for instance by pseudotyping the vectors with 
the envelope G-glycoprotein of vesicular stomatis virus (Chen eta!, 
1996) . By replacing the neomycin phosphotransferase selective 
marker gene with that of histidinol dehydrogenase, the problems 
associated with G418-induced terminal differentiation may be 
overcome (StockschHider et al, 1991) . Alternatively, enriclling the 
population of keratinocyte stem cells in culture prior to transduc-
tion, for instance by selecting for !ugh levels of {31 integrins Oones 
and Watt, 1993), may improve targeting of stem cells. Targeting 
the skin by i11 vivo gene transfer procedures is an attractive 
alternative to the ex vivo methods explored herein. Initial reports, 
however, using Hposomes and sensitive reporter assays (Alexander 
and Akhurst, 1995; Li and Hoffinan, 1995), although demonstrating 
feasibility, give little indication of efficiency. Further studies using a 
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therapeutic eDNA of interest are required if such methods are to 
become a practical reality. 
Although the decrease in transgene expression after keratinocyte 
transplantation (Flowers et al, 1990; Gerrard eta/, 1993; Jensen eta/, 
1994; Stockschlader et al, 1994; Choate et al, 1996; Fenjves et nl, 
1996) has commonly been attributed to promoter down-regulation, 
part of this decrease may have been caused by a declining survival 
of genetically modified cells over time. ln superficial grafting 
studies (Fenjves et al, 1996), tllis may be a result of graft shrinkage 
caused by competing host epidernlis . Altematively, when kerati-
nocytes are transplanted without selecting for transduced cells 
(Choate et al, 1996), a survival advantage of rare nontransduced 
cells may lead to a decreased proportion of transduced cells witllin 
the graft. In our study, transplanted cells were protected from 
competing host epidermis and transduced cells were selected in 
G418. By using the transplantation chamber, we observed lligher 
levels of £1ctor IX and were able to show that the subsequent 
decline in expression was due to encapsulation and possibly termi-
nal differentiation of the grafted kerat:inocytes . The fact that the 
HPV-16 enhancer vector produced levels of factor IX in 11itro 
comparable to the parent vector and that these levels were suffi-
ciently lligh to enable detection of recombinant factor IX in plasma 
indicates that this enhat1cer may be a. usefi.Il addition to expression 
vectors for keratinocyte gene therapy. It must be emphasized that 
although the formation of a stable epidennis after transplantation of 
keratinocytes to a xenogeneic (e.g., human to mouse) host has been 
demonstrated before (Boyce et al, 1996), long-term survival (> 8 
wk) using transduced keratinocytes has still not been demonstrated. 
Even if the maximum levels of 9 ng of human factor IX per ml 
detected in plasma in the mouse model herein could be maintained, 
this is only equivalent to - 0.2% of fuctor IX in normal human 
plasma, which is inadequate as a therapeutic dose for hemoplllliacs 
(Hedner and Davie, 1989). The graft area of - 100 mm2 available 
beneath the transplantation chamber, however, is only - 1% of the 
total surface area of the mouse (Alexander et a/, 1995). Therefore, 
increasing the graft to 10% of the total surface area would 
theoretically raise the clotting activity to - 2%, which approaches 
the ~4% factor IX that physicians presently aim for with conven-
tional factor IX replacement therapy regimens (Hedner and Davie, 
1989). Tlus, together with the recent evidence that factor IX 
secreted by retrovirally transduced keratinocytes is essentially com-
pletely biologically active (Gerrard et al, 1996), suggests that the 
epidermis remains an attractive target tissue for the gene therapy of 
hemopllilia B . 
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